Glioma is the most common brain cancer, and high-grade gliomas, including glioblastoma multiforme (GBM), are the most aggressive types of glioma. 1 The current standard treatment for GBM involves surgical resection followed by the administration of an alkylating agent, temozolomide, both concurrent with and after radiotherapy. Bevacizumab is administered as a second-line treatment after relapse. 2,3 However, GBM is resistant to chemotherapy and radiotherapy, with a median patient survival time of approximately one year. 1,4 The highly invasive nature of GBM cells is thought to contribute to the poor prognosis of this tumor, necessitating the exploration of alternative therapies. Many factors are involved in the migration and invasion of malignant tumors, including the nuclear factor of activated T cells (NFAT). [5][6][7] NFAT, originally found in activated T cells, is a transcription factor that induces gene transcription during the immune response. 8 The NFAT transcription factor family consists of five members: NFAT1 (NFATC2, NFATp),